The global pharmaceutical company Adalvo announced the acquisition of its first branded product, Onsolis® after concluding a deal with a reputable United States based specialty pharmaceutical Company, that originally owned the product. The brand is an opioid analgesic, indicated for the management of persistent breakthrough pain in cancer patients who have already received and are tolerant to opioid therapy for their underlying cancer pain.
What does the transaction mean for Adalvo?
Adalvo will be the exclusive owner of the brand and will obtain full rights to the product, taking over all existing business and all market authorizations globally, including in the US. The brand is currently being sold in several EU countries and in Taiwan by business partners. Adalvo will assume the supply responsibility and business continuity for these partners.
“This acquisition paves the way towards a transformative journey, at Adalvo. It is a real game changer, and we are thrilled to be venturing into the branded product domain, growing our position as a global partner of choice,” said Anil Okay, Chief Executive Officer of Adalvo.
“Our business remains fueled by our passion for relentless commitment to the partner network that we serve, and we will continue to bring high value assets to our portfolio, now also venturing into the branded product domain,” Okay further commented.